Literature DB >> 22286768

The ShcA SH2 domain engages a 14-3-3/PI3'K signaling complex and promotes breast cancer cell survival.

J Ursini-Siegel1, W R Hardy, Y Zheng, C Ling, D Zuo, C Zhang, L Podmore, T Pawson, W J Muller.   

Abstract

The ShcA adapter protein transmits activating signals downstream of receptor and cytoplasmic tyrosine kinases through the establishment of phosphotyrosine-dependent complexes. In this regard, ShcA possesses both a phosphotyrosine-binding domain (PTB) and Src homology 2 domain (SH2), which bind phosphotyrosine residues in a sequence-specific manner. Although the majority of receptor tyrosine kinases expressed in breast cancer cells bind the PTB domain, very little is known regarding the biological importance of SH2-driven ShcA signaling during mammary tumorigenesis. To address this, we employed transgenic mice expressing a mutant ShcA allele harboring a non-functional SH2 domain (ShcR397K) under the transcriptional control of the endogenous ShcA promoter. Using transplantation approaches, we demonstrate that SH2-dependent ShcA signaling within the mammary epithelial compartment is essential for breast tumor outgrowth, survival and the development of lung metastases. We further show that the ShcA SH2 domain activates the AKT pathway, potentially through a novel SH2-mediated complex between ShcA, 14-3-3ζ and the p85 regulatory subunit of phosphatidylinositol 3 (PI3') kinase. This study is the first to demonstrate that the SH2 domain of ShcA is critical for tumor survival during mammary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286768     DOI: 10.1038/onc.2012.4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  The SHCA adapter protein cooperates with lipoma-preferred partner in the regulation of adhesion dynamics and invadopodia formation.

Authors:  Alex Kiepas; Elena Voorand; Julien Senecal; Ryuhjin Ahn; Matthew G Annis; Kévin Jacquet; George Tali; Nicolas Bisson; Josie Ursini-Siegel; Peter M Siegel; Claire M Brown
Journal:  J Biol Chem       Date:  2020-04-16       Impact factor: 5.157

2.  Interaction with Shc prevents aberrant Erk activation in the absence of extracellular stimuli.

Authors:  Kin Man Suen; Chi-Chuan Lin; Roger George; Fernando A Melo; Eleanor R Biggs; Zamal Ahmed; Melanie N Drake; Swathi Arur; Stefan T Arold; John E Ladbury
Journal:  Nat Struct Mol Biol       Date:  2013-04-14       Impact factor: 15.369

3.  p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.

Authors:  Jesse Hudson; Jacqueline R Ha; Valerie Sabourin; Ryuhjin Ahn; Rachel La Selva; Julie Livingstone; Lauren Podmore; Jennifer Knight; Laura Forrest; Nicole Beauchemin; Michael Hallett; Morag Park; Josie Ursini-Siegel
Journal:  Mol Cell Biol       Date:  2014-07-28       Impact factor: 4.272

4.  ShcA Protects against Epithelial-Mesenchymal Transition through Compartmentalized Inhibition of TGF-β-Induced Smad Activation.

Authors:  Baby Periyanayaki Muthusamy; Erine H Budi; Yoko Katsuno; Matthew K Lee; Susan M Smith; Amer M Mirza; Rosemary J Akhurst; Rik Derynck
Journal:  PLoS Biol       Date:  2015-12-17       Impact factor: 8.029

5.  VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.

Authors:  Premalatha Shathasivam; Alexandra Kollara; Thomasina Spybey; Soyeon Park; Blaise Clarke; Maurice J Ringuette; Theodore J Brown
Journal:  Br J Cancer       Date:  2017-03-16       Impact factor: 7.640

6.  Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling.

Authors:  Chi-Chuan Lin; Kin Man Suen; Amy Stainthorp; Lukasz Wieteska; George S Biggs; Andrei Leitão; Carlos A Montanari; John E Ladbury
Journal:  Cancer Lett       Date:  2019-05-14       Impact factor: 8.679

7.  p52Shc regulates the sustainability of ERK activation in a RAF-independent manner.

Authors:  Ryo Yoshizawa; Nobuhisa Umeki; Akihiro Yamamoto; Mariko Okada; Masayuki Murata; Yasushi Sako
Journal:  Mol Biol Cell       Date:  2021-07-14       Impact factor: 4.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.